Amedisys
AMED
AMED was delisted on the 14th of August, 2025.
286 hedge funds and large institutions have $3.06B invested in Amedisys in 2022 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 99 increasing their positions, 105 reducing their positions, and 40 closing their positions.
126% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $6.27M
4.52% more ownership
Funds ownership: 92.87% → 97.39% (+4.5%)
3% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 40
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 288 → 286 (-2)
1% less capital invested
Capital invested by funds: $3.09B → $3.06B (-$29.4M)
6% less repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 105
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$128M |
| 2 |
Impax Asset Management Group
London,
United Kingdom
|
+$59.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$20.8M |
| 4 |
DM
Deerfield Management
New York
|
+$19.2M |
| 5 |
RP
Riverbridge Partners
Minneapolis,
Minnesota
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$47.7M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$35.5M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$11.5M |
| 4 |
Amundi
Paris,
France
|
-$11.4M |
| 5 |
Twin Tree Management
Dallas,
Texas
|
-$11.2M |
AMED Hedge Fund Activity: Q3 2022 in Review
286 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q3 2022, worth a combined $3.06B — down 0.95% from $3.09B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new AMED positions and 40 closed out — a net gain of 1 holder — while 99 added to existing stakes and 105 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $128M. The largest seller was T. Rowe Price Associates, cutting an estimated $47.7M.
- 286 institutional investors held Amedisys (AMED) as of Q3 2022, down from 288 in Q2 2022.
- Funds reported $3.06B of Amedisys stock for Q3 2022, down 0.95% quarter-over-quarter.
- 41 funds opened new Amedisys positions in Q3 2022 and 40 closed out, a net change of +1 holder.
- The largest Amedisys buyer in Q3 2022 was Point72 Asset Management, an estimated $128M added.
- The largest Amedisys seller in Q3 2022 was T. Rowe Price Associates, an estimated $47.7M sold.
Based on aggregated 13F filings for Q3 2022.